We seek to engage in ongoing dialogue with a broad range of industry and corporate experts to develop unique and differentiated sources of information. We look to identify investment alternatives that may be mispriced or misunderstood by the broader investing community.
Our strategies also specialize in creating detailed alternative scenario analysis that can highlight potential investment opportunities. Our evolving focus is on presenting those investment cases to institutional investors in a clear and concise fashion.
Supervisory Analyst - Equity Research
Jules Augus is the Supervisory Analyst in the Equity Research department of Aegis Capital Corp. His function is to approve research reports which provide information to the public in making investment decisions. The Supervisory analyst must verify that all communications with customers and the general public are in compliance with company guidelines and security industry standards and that information presented in company reports is accurate and complete. The Supervisory analyst engages with lead research analysts and their team to improve the quality of published research. Mr. Augus has a long and varied career on Wall Street as both a generalist analyst and Research Director. He was Research Director at Stuart Coleman from 1991-1999; at Investec Ernst from 1999-2002 and at Westrock Advisors from 2008-2010. He is a graduate of the Wharton School-University of Pennsylvania with a BS in Economics.
Head of Healthcare Equity Research
Mr. Weinstein is Head of Healthcare Equity Research at Aegis Capital Corp. Mr. Weinstein has over a decade of experience in equities. Mr. Weinstein was formerly Vice President, Institutional Equities and Head of Alpha Capture at CL King & Associates and an Institutional Equities Salesperson at Sidoti & Company. At those firms, Mr. Weinstein facilitated equity research distribution, proprietary long/short idea flow, and corporate access for mutual, pension, and hedge fund clients. Mr. Weinstein began his career as a research intern at NGN Capital, a life sciences venture capital fund. Mr. Weinstein graduated from Binghamton University with a BA in Economics and English, and from New York University’s Stern School of Business with an MBA (finance concentration). Additionally, Mr. Weinstein holds the CFA designation, and the Series 7, 63, 86, and 87 licenses.
Head of Consumer Products and Special Situations | Managing Director, Supervisory Analyst
Rommel Dionisio brings over 25 years of experience as a sell-side equity analyst, having previously worked at Merrill Lynch, FBR, and Wedbush Morgan. Mr. Dionisio is a nine-time honoree by the Thomson Reuters StarMine analyst ranking, a three-time All-Star on the Wall Street Journal’s Best of the Street annual survey, and a two-time honoree on Forbes’ Best Brokerage Analysts ranking. He frequently appears on CNBC, Bloomberg TV, and Fox Business, and is often quoted by numerous financial publications around the world. Mr. Dionisio received his BA and MBA degrees from Duke University, where he was the P. Huber Hanes, Jr. Scholar of his class.